Replies to post #168439 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Had to look this up:

Theoretically, site activation duration can be reduced to the time needed to activate a single site—100 days on average. (With improved planning and execution, that average can be reduced as well.) Since site activation uses two-thirds of enrollment cycle time, a 50 percent reduction in site activation time would reduce enrollment cycle time by 30 percent. And a 30 percent reduction in the current median enrollment cycle time of 490 days would amount to more than five months. I believe this is a number attractive to anyone in drug development.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143863176

From link provided by TTTAV:

http://www.pharmexec.com/site-activation-key-more-efficient-clinical-trials?pageID=1